Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
The ARAMIS phase III clinical trial found that darolutamide improved metastasis-free survival and overall survival in Black/African American patients. Darolutamide-treated patients had a higher three-year overall survival rate and longer time to disease progression compared to placebo-treated patients.
A clinical trial found that obese prostate cancer patients who underwent regular exercise training for 12 weeks had increased levels of anti-cancer myokines, which suppressed tumour growth and helped fight cancerous cells. The study suggests exercise may be a key weapon in cancer patients' battle against the disease.
Researchers mapped cancer through protein interactions, revealing biomarkers and potential new treatments for breast and head and neck cancers. The study provides a new definition of biomarkers based on large, multi-protein complexes, offering a more precise way to explain mutation effects.
Researchers identified two subtypes of metastatic prostate cancer that respond differently to hormone treatment. Luminal tumors responded better to testosterone-blocking treatments, while basal tumors did not benefit as much from this hormone treatment.
Novartis presents Phase III MONALEESA-2 study results demonstrating improved overall survival with Kisqali (ribociclib) in combination with letrozole. The analysis shows a statistically significant and clinically meaningful improvement in survival, with median OS of 63.9 months.
A novel combination of abiraterone acetate and prednisolone has been shown to prolong survival in patients with hormone/castration-sensitive prostate cancer. Studies PEACE-1 and STAMPEDE found that the addition of these drugs to standard therapy lengthened survival compared to standard therapy alone.
A new study found that genome-wide association studies (GWAS) results from people with European ancestry can still be applied to predict breast and prostate cancer risk in diverse groups. However, the findings emphasize the need for more diverse participants in GWAS analyses to realize the full potential of polygenic risk scores.
Research finds prostate cancer risk among 9/11 responders is 24% higher, with highest risk among earliest responders. The study also reveals a shorter latency period from exposure to disease development compared to other studies.
A study analyzing 6,775 patients with low-risk prostate cancer found that cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment. The study also found that higher Gleason grade, PSA level, tumor stage, and number of positive biopsy cores are related to shorter conversion times.
Firefighters who worked at the World Trade Center site after 9/11 are 13% more likely to develop cancer, particularly prostate and thyroid cancer. They were also diagnosed at a younger age, on average, with early-stage disease. The exact cause of this increased risk is unclear.
Researchers identify molecular targets for improved prostate cancer therapy by comparing genomic changes in cancer cells eradicated and resistant to treatment. The study also finds L1 retrotransposition as a dynamic source of cancer heterogeneity.
Researchers at Tampere University identified a specific population of treatment-resistant cells that persists in prostate cancer tissue. This finding suggests that the presence of these cells can predict patient responses to treatment and may help tailor treatment for different subgroups of patients.
Researchers at Flinders University have identified a protein called 6PGD that supports the survival of prostate cancer cells when challenged with hormonal therapy. The study found that 6PGD inhibitors can kill cancer cells in lab dishes and real tumours, offering new hope for targeted therapies
A population-based study found that nearly half of men with low-risk prostate cancer transitioned from active surveillance to definitive treatment within five years after diagnosis. The study, published in The Journal of Urology, analyzed data from 8,541 men and identified factors associated with the likelihood of transition, including...
Monash University researchers have established a vast collection of living prostate cancer tumors from patients, enabling the testing of new treatments and advancing patient care. The PDX collection comprises 59 tumors collected from 30 patients between 2012-2020, providing a unique resource for scientists and pharmaceutical companies.
A recent study reveals that some prostate cancer survivors experience a persistent fear of cancer recurrence (FCR) even many years after diagnosis and treatment. The study identified patient and clinical risk factors linked with FCR, highlighting the need for ongoing monitoring and psychosocial care.
A recent study published in European Journal of Epidemiology reveals that widowers are at a higher risk of being diagnosed with advanced prostate cancer. The research highlights the importance of social environment and lifestyle factors in the development of the disease.
A novel blood test, Stockholm3, can reduce the number of MRIs performed by a third while preventing the detection of minor, low-risk tumours. The addition of this test to MRI reduces overdiagnosis by as much as 69% and halves the number of biopsies.
Researchers have found a way to harness the power of immunotherapy for advanced prostate cancer by targeting a protein called PIKfyve. Blocking PIKfyve with the inhibitor ESK981 has been shown to increase tumor death and recruit immune T cells, offering new hope for patients with this challenging form of cancer.
The American Academy of Family Physicians is investigating an 'educational' session promoting dairy products linked to increased risk of prostate cancer and other diseases disproportionately affecting African Americans. The Physicians Committee for Responsible Medicine filed a complaint, citing standards set by the Accreditation Counci...
A new genomic test may help identify patients at high risk of prostate cancer progression. The Decipher Biopsy test showed that men with high scores needed active treatment sooner, and those who underwent surgery had shorter time until PSA levels increased or they were put on anti-androgen therapy.
A study of 647 patients with untreated nonmetastatic prostate cancer found that Black men underwent significantly fewer prostatectomies during the pandemic compared to white patients. Prior to the pandemic, there was no difference in treatment rates between the two groups.
New research suggests that closely monitoring low-risk prostate cancer can be as effective as active treatment in reducing mortality rates and preserving sexual function. This approach allows men to live with the disease for ten years or more without treatment, while still being unlikely to die from it.
A phase 3 trial found that Lu-PSMA-617 significantly improved survival and progression-free survival of patients with metastatic castration-resistant prostate cancer. The treatment delivered beta radiation directly to tumour cells, keeping them alive for longer than standard care.
A new AI-powered diagnostic tool can spot asymptomatic prostate cancer in routine CT scans, allowing for earlier diagnosis and improved treatment outcomes. The technology, developed at RMIT University, has been shown to perform better than human radiologists in detecting cancerous growths.
Researchers developed a miniature 3D bone-like tissue model to investigate the effects of anti-androgen therapies on prostate cancer bone tumours. The study found that traditional therapy had limited effect, with interactions between cancer cells and the bone microenvironment significantly impacting disease progress.
A new 'nomogram' helps predict which men with advanced metastatic prostate cancer will respond favorably to LuPSMA, a targeted therapy. The tool analyzes imaging and clinical data to stratify patients into high-risk or low-risk groups, enabling more personalized treatments.
Men with high-risk prostate cancer benefit from multimodality care, which includes hormone therapy and radiation. The study found significant differences in deaths when guideline-concordant multimodality care was not delivered.
A new study found that Black men are 11% less likely to receive advanced prostate cancer therapies compared to non-Black men. Despite equal access to healthcare services, the disparity persists, with Black men also being more likely to die from the disease than non-Black patients.
Researchers identified a subset of localized prostate cancers that exhibit characteristics typical of 'hot' tumors, which may respond to immunotherapies. The study found that about a quarter of high-risk prostate cancers have these immunologic traits, suggesting a substantial number of patients may benefit from immunotherapy.
Researchers identify lineage plasticity as a deadly identity switch in castration-resistant prostate cancers, which can behave like small cell lung cancer. BET bromodomain inhibitors show promise in blocking this switch and overcoming treatment-emergent neuroendocrine prostate cancer.
A phase III clinical trial validates the effectiveness of 18F-DCFPyL in detecting and localizing recurrent prostate cancer, achieving high positive predictive values across various regions. The study's results support the use of PSMA-targeted radiotracers as the most sensitive and accurate agents for imaging prostate cancer.
Abdominal obesity is associated with an increased risk of developing aggressive prostate cancer, while general obesity does not show the same correlation. The research team recommends prioritizing studies on obesity exposure over a lifetime and further analysis of body fat distribution to better understand the risks.
Researchers identified glypican-1 protein that prevents cancer cells from spreading to bone, reducing aggressiveness. The study provides a potential new target for future treatments and supports previous findings suggesting the protein's role in preventing tumor growth.
A new treatment option has been developed to improve survival and disease control in men with advanced prostate cancer. The targeted radioligand therapy significantly extended survival and delayed progression, with a substantial effect given the high progression of disease despite previous treatments.
A nationwide Swedish study found that men with a family history of prostate cancer reach the screening risk threshold up to 12 years earlier than previously recommended, suggesting personalized screening approaches. The research suggests refining age guidelines for early screening based on individual family history factors.
Researchers have identified a promising drug target for treating and preventing aggressive, drug-resistant prostate cancer. Inhibiting the protein H6PD leads to significantly reduced tumor sizes and improved survival among mouse models with drug-resistant prostate cancer.
Researchers found that areas with low environmental quality had stronger associations with late-stage prostate cancer diagnoses, particularly in Black men. The study suggests that addressing environmental factors such as land, water, and sociodemographic variables could improve treatment outcomes.
Researchers at UVA Cancer Center have unveiled new insights into how hormones known as androgens act on cells, which could lead to improved treatments for prostate, ovarian, and breast cancers. The study found that a complex signaling system regulates androgen receptor activity, using an enzyme called Parp7.
Researchers enrolled 50 Black and 50 white men with advanced prostate cancer to test hormone therapy abiraterone acetate plus prednisone. They found that Black men's PSA levels dropped further and more frequently, but disease progression and survival times were similar.
A new clinical trial is investigating the effectiveness of white button mushroom tablets in regulating immune systems and reducing prostate-specific antigen (PSA) levels. The study aims to recruit 132 male participants with recurrent prostate cancer, with results indicating potential benefits against prostate cancer.
A new study found a 36% decrease in prostate cancer diagnoses in Sweden during the first pandemic wave, with most pronounced declines among men aged 75 and over. The number of patients receiving curative treatment remained unaffected, suggesting that healthcare prioritized cancer care during the pandemic.
Researchers have developed a new urine test called ExoGrail, which shows how aggressive prostate cancer is and can reduce unnecessary biopsies. The test uses biomarkers to provide risk scores and identify patients who need invasive biopsies.
Researchers have discovered a new way to transform tissue surrounding prostate tumors to help the immune system fight cancer. The technique, called epigenetic reprogramming, could lead to improvements in immunotherapy treatments for prostate cancer.
Researchers at CU Cancer Center have discovered that tumor-suppressing genes MAP3K7 and CHD1 deletion increases androgen receptor signaling, making patients less responsive to anti-androgen therapy. This knowledge could lead to personalized treatment approaches for men with aggressive prostate cancer.
Tumor gene profiling decreases patient acceptance of active surveillance among men with clinically similar prostate cancers and low health literacy, a new study found. The study suggests that education on prostate cancer treatment options is needed for this population.
Research reveals associations between circulating tumor cell (CTC) mutations and clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC). The study identified novel genetic alterations linked to response to AR inhibitors, including gains of ATM, NCOR2, and HSD17B4, which were associated with sensitivity to treatment.
Researchers at Duke University Medical Center identified a key reason hormone therapies fail and proposed a new treatment strategy directly targeting the cancer's fuel source, glutamine. By inhibiting glutamine utilization, tumor growth is successfully inhibited in studies using prostate cancer cell lines and animal models.
A mouse study suggests that white button mushroom extract can suppress androgen receptor activity in prostate cancer cells. The study also found that mice treated with the extract experienced reduced prostate tumor growth and decreased levels of PSA in their blood.
Researchers discovered microRNA-4287 inhibits prostate cancer's progression and metastasis, leading to increased cell cycle arrest. The study found miR-4287 specifically targets SLUG and CD44, suggesting a potential diagnostic and therapeutic tool against advanced prostate cancer.
A new study suggests that targeted screening for prostate cancer could prevent up to 16% of prostate cancer deaths and reduce overdiagnosis by 27%. The study, led by UCL researchers, recommends screening men with a high genetic risk profile using an MRI scan before biopsy.
A $1.06 million grant has been awarded to LSU Health New Orleans School of Medicine to explore a new treatment for Castrate Resistant Prostate Cancer (CPRC). The research focuses on the role of Prostate Derived ETS Transcription Factor (PDEF) in prostate cancer, with the goal of identifying novel targets for intervention.
The Cleveland African American Prostate Cancer Project aims to reduce health disparities by increasing prostate cancer screening among African American men. The project will develop and implement a comprehensive, sustainable program to screen for prostate cancer using barbershops as community hubs.
A genetic tool has been validated to estimate age of onset for aggressive prostate cancer in diverse ethnic/racial groups, with improved performance in men of African ancestry. The polygenic hazard score demonstrated excellent performance across European, Asian, and African genetic backgrounds.
Research from Baylor College of Medicine reveals that inhibiting MAPK4 can simultaneously activate and inhibit key cellular signaling pathways driving prostate cancer growth, suggesting a novel therapeutic strategy. This approach may provide a more effective treatment for advanced prostate cancer.
A new review highlights biological differences in prostate cancer development across ethnicities, identifying potential improvements for African American men. The study aims to reduce incidence and mortality rates by leveraging these differences.
Scientists at MIT develop system that detects chemical and microbial content of air samples with greater sensitivity than a dog's nose. The miniaturized detection system, coupled with machine-learning process, can identify distinctive characteristics of disease-bearing samples, matching success rates of dogs in detecting prostate cancer.
A cross-disciplinary study combines canine olfaction with other detection methods to improve prostate cancer diagnosis. Dogs showed 71% sensitivity in detecting aggressive prostate cancer from urine samples, and an artificial neural network replicated their performance using spectroscopy data analysis.
Researchers created a model to identify patients with high-risk prostate cancer who will benefit from the PSMA PET scan. The study found that patients with a Gleason score of 9 or 10 and high percent positive cores are most likely to benefit from the scan.
New research from Edith Cowan University found that exercise helps men with prostate cancer reduce symptoms of depression and anxiety, regardless of the type or intensity of exercise. The study suggests that supervised exercise is more beneficial than unsupervised exercise in reducing psychological distress.